This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.



Aventis Docket No. FRAV2002/0022US NP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Branislav MUSICKI

Examiner: To Be Assigned

Serial No.: 10/655,364

Group Art Unit: To Be Assigned

Filed:

September 4, 2003

Title:

Novel heterocyclic compounds,

preparation process and intermediates, and use as medicaments, in particular as B-lactamase inhibitors and antibacterials

POWER OF ATTORNEY FOR PATENT APPLICATION

Mail Stop Missing Parts Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

I, Y. DAV. 1, an Authorized Signatory of Aventis Pharma S.A., Assignee of the aboveidentified Application, hereby appoint the attorneys and/or agents associated with the Customer No.(s) provided below as attorneys and/or agents with full power to prosecute this application on behalf of Assignee and to transact all of Assignee's business in connection with the above-identified Application in the Patent and Trademark Office:

Customer No.: 005487

Effective Date: September 4, 2003

Address correspondence and telephone calls to: Irving Newman, Reg. No. 22,638

Aventis Pharmaceuticals Inc.

Patent Department

Route #202-206 / P.O. Box 6800

Bridgewater, New Jersey 08807-0800

Telephone (908) 231-2785

Telefax

(908) 231-2626

-JAN. 6. 2004 3:02PM

UNITED STATES OF AMERICA

DECLARATION FOR PATENT APPLICATION

As a below named inventor(s), I/We hereby declare that: My/Our residence(s), post office address(es) and citizenship(s) are as stated below my name(s), I/We verily believe I am/we are the original, first and sole/joint inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled: Novel heterocyclic compounds, preparation process and intermediates, and use as medicaments, in particular as B-lactamase inhibitors and antibacterials and the specification of which is attached hereto (Aventis Docket No.FRAV2002/0022US NP) 図 (check one) was filed on 4 September 2003 as U.S. Application Number 10/655,364 and was amended on (if applicable).

was described and claimed in PCT Int'l Application Number and as amended under PCT Article 19 on (i filed on IWe hereby state that I/We have reviewed and understand the contents of the above identified specification, including the claims as amended by any amendment referred to above. I/We acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 C.F.R. 1.56. (if any). I/We hereby claim foreign priority benefits under Title 35, United States Code §119(a)-(d) or 385 (b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at the application on which priority is claimed. I/We have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed: \boxtimes Foreign 02 10957 France Country 5 September 2002 Day/Month/Year Filed Priority: Number Prior Foreign Number Country Day/Month/Year Filed Appin(s): I/We hereby claim the benefit under Title 35, United States Code §119(e) of any United States Provisional application(s) listed below: Number Filing Date I/We hereby claim the benefit under Title 35, United States Code §120 or 365(c) of any United States application(s) or international application designating the United States listed below and, insofar as the subject provided by the first paragraph of Title 35, United States Code §112, I/We acknowledge the duty to disclose in Title 37, Code of Federal Regulations §1.56 which this application. Application Serial No. Filing Date Status (Patented, Pending) I/We hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States code §1001, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. Additional names and signatures are attached. inventors(s), 1. Full name: Branislav MUSICKI 2. Full name: Signature: Signature; ___ Country of Citizenship: France Date: Residence: Paris, France Country of Citizenship: Residence: (City and State/City and Country only) (City and State/City and Country only) P. O. Address: 4 rue de Louvois P. O. Address: 75002 Paris, France

Full flame;	4. Full name:
Signature: Date: Country of Citizenship: Residence: (City and State/City and Country only) P. O. Address:	Signature: Date: Country of Citizenship: Residence: (City and State/City and Country only) P. O. Address:
5. Full name:	6. Full name:

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206
P.O. Box 6800
Mail Code D-303A
Bridge water, NJ 08807-0800
Telephone (908) 231-2785
Telefax (908) 231-2626

Aventis Docket No. FRAV2002/0022US NP